Acceleron drops a development program as #2 drug fails to spark functional benefits in patients with a rare neuromuscular ailment
Acceleron is scrapping a muscular dystrophy development program underway for its number 2 drug in the pipeline after pouring over some failed mid-stage secondary data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.